In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease
This study investigated the in vivo properties of two heavy chain antibody fragments (V(H)H), ni3A and pa2H, to differentially detect vascular or parenchymal amyloid-β deposits characteristic for Alzheimer's disease and cerebral amyloid angiopathy. Blood clearance and biodistribution including brain uptake were assessed by bolus injection of radiolabeled V(H)H in APP/PS1 mice or wildtype littermates. In addition, in vivo specificity for Aβ was examined in more detail with fluorescently labeled V(H)H by circumventing the blood-brain barrier via direct application or intracarotid co-injection with mannitol. All V(H)H showed rapid renal clearance (10-20 min). Twenty-four hours post-injection (99m)Tc-pa2H resulted in a small yet significant higher cerebral uptake in the APP/PS1 animals. No difference in brain uptake were observed for (99m)Tc-ni3A or DTPA((111)In)-pa2H, which lacked additional peptide tags to investigate further clinical applicability. In vivo specificity for Aβ was confirmed for both fluorescently labeled V(H)H, where pa2H remained readily detectable for 24 hours or more after injection. Furthermore, both V(H)H showed affinity for parenchymal and vascular deposits, this in contrast to human tissue, where ni3A specifically targeted only vascular Aβ. Despite a brain uptake that is as yet too low for in vivo imaging, this study provides evidence that V(H)H detect Aβ deposits in vivo, with high selectivity and favorable in vivo characteristics, making them promising tools for further development as diagnostic agents for the distinctive detection of different Aβ deposits.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2012 |
---|---|
Erschienen: |
2012 |
Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
---|---|
Enthalten in: |
PloS one - 7(2012), 6 vom: 26., Seite e38284 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Nabuurs, Rob J A [VerfasserIn] |
---|
Links: |
---|
Themen: |
Amyloid beta-Peptides |
---|
Anmerkungen: |
Date Completed 11.10.2012 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1371/journal.pone.0038284 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM21842437X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM21842437X | ||
003 | DE-627 | ||
005 | 20231224040413.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2012 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pone.0038284 |2 doi | |
028 | 5 | 2 | |a pubmed24n0728.xml |
035 | |a (DE-627)NLM21842437X | ||
035 | |a (NLM)22675537 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Nabuurs, Rob J A |e verfasserin |4 aut | |
245 | 1 | 0 | |a In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease |
264 | 1 | |c 2012 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.10.2012 | ||
500 | |a Date Revised 21.10.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a This study investigated the in vivo properties of two heavy chain antibody fragments (V(H)H), ni3A and pa2H, to differentially detect vascular or parenchymal amyloid-β deposits characteristic for Alzheimer's disease and cerebral amyloid angiopathy. Blood clearance and biodistribution including brain uptake were assessed by bolus injection of radiolabeled V(H)H in APP/PS1 mice or wildtype littermates. In addition, in vivo specificity for Aβ was examined in more detail with fluorescently labeled V(H)H by circumventing the blood-brain barrier via direct application or intracarotid co-injection with mannitol. All V(H)H showed rapid renal clearance (10-20 min). Twenty-four hours post-injection (99m)Tc-pa2H resulted in a small yet significant higher cerebral uptake in the APP/PS1 animals. No difference in brain uptake were observed for (99m)Tc-ni3A or DTPA((111)In)-pa2H, which lacked additional peptide tags to investigate further clinical applicability. In vivo specificity for Aβ was confirmed for both fluorescently labeled V(H)H, where pa2H remained readily detectable for 24 hours or more after injection. Furthermore, both V(H)H showed affinity for parenchymal and vascular deposits, this in contrast to human tissue, where ni3A specifically targeted only vascular Aβ. Despite a brain uptake that is as yet too low for in vivo imaging, this study provides evidence that V(H)H detect Aβ deposits in vivo, with high selectivity and favorable in vivo characteristics, making them promising tools for further development as diagnostic agents for the distinctive detection of different Aβ deposits | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
650 | 7 | |a Immunoglobulin Fragments |2 NLM | |
650 | 7 | |a Immunoglobulin Heavy Chains |2 NLM | |
700 | 1 | |a Rutgers, Kim S |e verfasserin |4 aut | |
700 | 1 | |a Welling, Mick M |e verfasserin |4 aut | |
700 | 1 | |a Metaxas, Athanasios |e verfasserin |4 aut | |
700 | 1 | |a de Backer, Maaike E |e verfasserin |4 aut | |
700 | 1 | |a Rotman, Maarten |e verfasserin |4 aut | |
700 | 1 | |a Bacskai, Brian J |e verfasserin |4 aut | |
700 | 1 | |a van Buchem, Mark A |e verfasserin |4 aut | |
700 | 1 | |a van der Maarel, Silvère M |e verfasserin |4 aut | |
700 | 1 | |a van der Weerd, Louise |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 7(2012), 6 vom: 26., Seite e38284 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2012 |g number:6 |g day:26 |g pages:e38284 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0038284 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 7 |j 2012 |e 6 |b 26 |h e38284 |